Dechra is an international specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide.

We have made excellent progress since setting our priorities for each Growth Driver in 2013.

2014

Commenced trading in

Italy

2014

Acquired

PSPC

US bolt-on

Percentage of revenue made from outside Europe

Percentage of revenue made outside Europe 2013

2013

16%

Percentage of revenue made outside Europe 2018

2018

42%

Underlying operating profit margin

Undelying operating profit 2013

2013

9.6%

Underlying operating profit 2018

2018

24.4%

2015

Commenced trading in

Canada and Poland

2015

Acquired

Genera

Entry into poultry vaccines

2016

Acquired

Putney

Transformational US deal

2016

Acquired

Apex

Access to Australian CAP market

Number of countries distributed to

2013

40

2018

50

Map of countries distributed to

Number of countries with own sales and marketing organisations

2013

13

2018

24

Folder icon

2017

Acquired 33% of

Medical Ethics

Access to novel product development

2017

Acquired

RxVet

Access to New Zealand

2018

Acquired

AST Farma

Strengthens Dutch market position and provides direct-to-vet relationship

Le Vet

Adds to EU product portfolio

Number of product registrations

2013 1,327

2018 4,680